ライフサイエンスコーパス: biopsy-proven

1 te in the diagnosis of both types of tumors (biopsy-proven).

2 loped transformed lymphoma, of which 51 were biopsy proven.

3 th A-AION secondary to giant cell arteritis (biopsy-proven), 20 patients with NA-AION, and 20 control

4 The outcomes of 20 patients with FMF and biopsy-proven AA amyloidosis that were transplanted betw

5 NK cell subset was strongly associated with biopsy-proven ACR (hazard ratio, 10.7; P = 0.02).

6 onths, and 11 (23.9%) recipients experienced biopsy-proven ACR.

7 From 1981 to 2009, 82 patients with biopsy-proven active myocarditis were consecutively enro

8 evolution of a large sample of patients with biopsy-proven active myocarditis, looking for accessible

9 Incidence of biopsy proven acute rejection was 18.5%.

10 lant treatment failure rate, a composite of: biopsy-proven acute AMR (Banff 2007 grade II or III; ass

11 ed treatment of 13 consecutive patients with biopsy-proven acute AMR with intravenous cyclophosphamid

12 , timing, surgical techniques, outcomes, and biopsy-proven acute cellular rejections (ACRs) in 46 adu

13 Rates of biopsy-proven acute rejection (5.7% vs 7.9%), adverse ev

14 loss (aHR, 1.68 [1.08-2.62]; P = 0.022) and biopsy-proven acute rejection (aHR, 1.71 [1.13-2.60]; P

15 Less biopsy-proven acute rejection (AR) (p = 0.005), cytomega

16 oportion of patients who experienced treated biopsy-proven acute rejection (BPAR) during the first ye

17 Cumulative rates of biopsy-proven acute rejection (BPAR) from first randomiz

18 us trough concentration and the incidence of biopsy-proven acute rejection (BPAR) in 216 moderately s

19 At that time, the rate of biopsy-proven acute rejection (BPAR) of the pancreas was

20 Biopsy-proven acute rejection (BPAR) rates and types wer

21 Biopsy-proven acute rejection (BPAR) rates and types wer

22 dose [mg]/trough concentration [mug/L]) and biopsy-proven acute rejection (BPAR) the first 90 days p

23 antation to last follow-up, the incidence of biopsy-proven acute rejection (BPAR) was 77% (37/48) and

24 Breakthrough CMV, resistant CMV, biopsy-proven acute rejection (BPAR), graft loss, opport

25 tcomes, including delayed graft function and biopsy-proven acute rejection (BPAR).

26 the impact of PPI use on the 1-year rates of biopsy-proven acute rejection (BPAR).

27 ter results for mTORi versus MPA in terms of biopsy-proven acute rejection (hazard ratio [confidence

28 Biopsy-proven acute rejection (odds ratio [OR] 2.32, 95%

29 prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR) during TAC withdra

30 There were no significant differences in biopsy-proven acute rejection (two trials, n=1093; risk

31 The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or dea

32 ncidence of a co-primary efficacy end point (biopsy-proven acute rejection [BPAR], graft loss, or dea

33 ter results for mTORi versus MPA in terms of biopsy-proven acute rejection [Hazard Ratio (HR)(Confide

34 Biopsy-proven acute rejection and acute rejection were s

35 Endpoints included development of biopsy-proven acute rejection and analysis of graft surv

36 eatment efficacy defined as the incidence of biopsy-proven acute rejection and estimated creatinine c

37 To evaluate clinical factors associated with biopsy-proven acute rejection during the first post-tran

38 (A24-MFI 970; biopsy for cause did not show biopsy-proven acute rejection or microinflammation score

39 e of composite efficacy failure (graft loss, biopsy-proven acute rejection or severe graft dysfunctio

40 Biopsy-proven acute rejection was diagnosed in 21 patien

41 The 1-year incidence of biopsy-proven acute rejection was monitored.

42 A lower incidence of biopsy-proven acute rejection was seen in patients recei

43 ar filtration rate at 12 months and rates of biopsy-proven acute rejection were also similar between

44 n patterns were compared among patients with biopsy-proven acute rejection, borderline changes, and i

45 no difference in renal function or rates of biopsy-proven acute rejection, graft loss, opportunistic

46 The composite efficacy endpoint of treated biopsy-proven acute rejection, graft loss, or death was

47 Secondary endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or death), de

48 cacy failure endpoint was graft loss, death, biopsy-proven acute rejection, or lost to follow-up.

49 Two years after transplantation, the biopsy-proven acute rejection-free survival was worse in

50 in terms of renal function, proteinuria, or biopsy-proven acute rejection.

51 levels of GDF15 to an increased incidence of biopsy-proven acute rejection.

52 eaths (3 [4.7%] vs 17 [21.9%], P = .007) and biopsy-proven acute rejections (15 [23.4%] vs 31 [48.4%]

53 Patient survival and biopsy-proven acute rejections were statistically simila

54 Two were biopsy-proven acute rejections with subsequent graft fai

55 Postoperative hemodynamics, biopsy-proven acute rejections, and mortality were simil

56 index of the primary tumor in patients with biopsy-proven adenocarcinoma or squamous cell carcinoma

57 ents with follicular lymphoma and subsequent biopsy-proven aggressive histology transformation.

58 One hundred forty-two patients with biopsy-proven AH that survived the first episode were in

59 studied a cohort including 162 patients with biopsy-proven AH.

60 prospective study included 40 subjects with biopsy-proven AL amyloidosis including active AL amyloid

61 Patients with biopsy-proven AL cardiac amyloid, who presented with hea

62 70 years who were heavy drinkers with severe biopsy-proven alcoholic hepatitis, as indicated by recen

63 Patients with acute biopsy-proven alloreactivity according to the Banff clas

64 e biomarker for risk stratification of acute biopsy-proven alloreactivity in kidney transplant recipi

65 ed trial, we randomly assigned patients with biopsy-proven AMR to receive rituximab (375 mg/m) or pla

66 e proven localised amyloidosis classified as biopsy proven amyloid deposition confined to one site or

67 IV)-infected adults aged >=27 years with 1-3 biopsy-proven anal HSILs (index HSILs) without prior his

68 Thirteen cases were biopsy proven, and 2 cases were presumed on the basis of

69 ne-mediated graft injury (chronic rejection, biopsy proven, and suspected late acute rejection) after

70 tive sera from 34 kidney recipients, 19 with biopsy-proven antibody-mediated rejection (AMR) + and 15

71 analyses restricted to subgroups with either biopsy-proven, antibody-mediated, or vascular rejection,

72 t/graft survival and cumulative incidence of biopsy proven AR.

73 and a comparator cohort of 25 patients with biopsy-proven ATTR V122I amyloidosis recruited from Sept

74 In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atria

75 patients who present with palpable or needle biopsy-proven axillary metastases, patients with positiv

76 ctive study reports outcomes for adults with biopsy-proven B-cell PTLD treated initially with R-Mono

77 Diagnosis of PTLD was biopsy-proven based on World Health Organization histolo

78 WA women aged between 40 and 70 years with a biopsy-proven BBD diagnosis.

79 nd innumerable cutaneous BCCs presented with biopsy-proven BCC in his lungs.

80 n field 10 months after undergoing ESB for a biopsy-proven BCC.

81 6 cases of biopsy-proven cancer, 35 cases of biopsy-proven benign lesions, and 52 normal or benign ca

82 zed for 51 cancer cases and 51 controls with biopsy-proven benign lesions, matched by age and year-of

83 a multicenter cohort comprising 50 cases of biopsy-proven BKPyVAN compared to previously published c

84 occurred in 49 (15.8%) of 311 patients, and biopsy-proven BKPyVAN in 14 (4.5%) of 313.

85 SAs), especially in combination with ongoing biopsy-proven BKPyVAN on follow-up, did correlate with g

86 n children with persistent BKPyV-DNAemia and biopsy-proven BKPyVAN with need for therapeutic interven

87 from those with persisting BKPyV-DNAemia and biopsy-proven BKPyVAN, who would benefit from individual

88 We analyzed 40 patients with biopsy-proven BPH who underwent a second prostate biopsy

89 IPAA-compliant prospective study, women with biopsy-proven breast cancer underwent MRI, CEM, and MBI

90 Fifty adult patients with MIg and biopsy-proven C3G were extracted from the French nationa

91 which 40 were patients with newly diagnosed, biopsy-proven CA (65.5+/-10.8 years, 65% male, 62.5% amy

92 The cohort included 36 cases of biopsy-proven cancer, 35 cases of biopsy-proven benign l

93 ave undergone active surveillance (including biopsy-proven cancers) and a better understanding of how

94 domized clinical trial open to patients with biopsy-proven carcinoma of the esophagus.

95 utcome of IPH by retrospectively studying 69 biopsy-proven cases of IPH.

96 Given the limited number of biopsy-proven cases with ethnically matched controls, we

97 erformed including 463 Spanish patients with biopsy-proven CD.

98 oma or anaplastic large-T-cell lymphoma, had biopsy-proven CD30-positive tumours, had an Eastern Coop

99 analyzed serum samples from 90 patients with biopsy-proven CeD and 79 healthy individuals (controls)

100 in 2 US centers (Boston, MA), 14 adults with biopsy-proven CeD were randomized to 3 g or 10 g gluten/

101 Forty-one children with biopsy-proven celiac disease (median age, 9 years old; 1

102 ed at examining the annual incidence rate of biopsy-proven celiac disease among children in Sweden ov

103 ro-conversion was 8/205 and the incidence of biopsy-proven celiac disease cases was 5/205.

104 a total of 634 first degree relatives of 186 biopsy-proven celiac disease patients diagnosed between

105 530 children with biopsy-proven celiac disease were included.

106 Then, in the intervention study, adults with biopsy-proven celiac disease were randomly assigned to g

107 All (4 of 4) DSCI patients had biopsy-proven chronic allograft injury and/or recurrence

108 groups (8/43, 14/43, and 12/42, P=0.34), but biopsy-proven chronic allograft injury incidence was sig

109 olic cirrhosis and, 6 years later, developed biopsy-proven chronic HEV infection.

110 Biopsy-proven chronic orbital inflammation was present i

111 ers in France, with HCV or HBV infection and biopsy-proven cirrhosis, Child-Pugh A scores, no previou

112 All patients had HCV infection and biopsy-proven cirrhosis, were Child-Pugh class A, and ha

113 against 21 board-certified dermatologists on biopsy-proven clinical images with two critical binary c

114 To characterize oscillometry measurements in biopsy-proven clinically significant (grade >=2 ACR) in

115 2017 through November 2017), 52 adults with biopsy-proven colorectal cancer and suspected hepatic me

116 Eight hundred twenty-two patients with biopsy-proven colorectal cancer, who underwent (18)F-FDG

117 s (mean age: 54.3+/-11 years; 55% male) with biopsy-proven COP in a tertiary lung center between 2009

118 17, 20, 24, 36, and 38 association with skin biopsy proven cSCC.

119 ty dermoscopic images of 20 outpatients with biopsy-proven cutaneous metastases and known diagnosis o

120 With median follow-up of 95 months, biopsy-proven cute rejection incidence was similar in th

121 Women with biopsy-proven DCIS corresponding to a unifocal microcalc

122 unted in 40 urine samples from patients with biopsy-proven definitive PVN.

123 e months to years before documented NNRP and biopsy-proven diagnosis in patients with MN.

124 urthermore, we review the published cases of biopsy-proven disseminated histoplasmosis with cholestat

125 ed, and no deaths from melanoma arising from biopsy-proven DN occurred through the latest dermatology

126 January 1, 2014, and December 31, 2016, with biopsy-proven EMPD in whom HRCM was used to monitor trea

127 hods Fifty-three consecutive patients with a biopsy-proven extracardiac diagnosis of systemic sarcoid

128 Sixteen patients of biopsy-proven eyelid malignancy (7 squamous cell carcino

129 267 consecutive patients with biopsy proven fatty liver or non-alcoholic steatohepatit

130 Acute rejections and the biopsy-proven findings disqualifying patients from IS wi

131 rd-approved database was queried to identify biopsy-proven first AR episodes occurring from January 2

132 ed YAP protein in glomeruli of patients with biopsy-proven focal segmental glomerulosclerosis (FSGS).

133 3 of 25 temporal arteries from patients with biopsy-proven GCA.

134 Eighteen patients with biopsy-proven GEP-NETs were evaluated with (68)Ga-DOTANO

135 16 through May 2017, study participants with biopsy-proven glomerulonephritis were prospectively exam

136 of all organs were at an increased risk for biopsy-proven graft rejection within 4 weeks after detec

137 We correlated CMV infection, biopsy-proven graft rejection, and graft loss in 1,414 p

138 predictors of the hazard rate of developing biopsy-proven GVHD during the first 60 months posttransp

139 ging Reporting and Data System category 5 or biopsy-proven HCC and who were undergoing TAE were enrol

140 the dermatology department for a subsequent biopsy-proven head and neck malignancy through April 201

141 ethods From January to June 2019, women with biopsy-proven HER2-negative primary breast cancer and bi

142 Of these 5 patients, 2 had biopsy-proven HER2-positive metastases and went on to be

143 Of these six women, three had biopsy-proven HER2-positive metastases, two had patholog

144 Patients with biopsy-proven high-grade dysplasia or esophageal cancer

145 We identified 6 patients with biopsy-proven high-risk prostate cancer who were referre

146 Superimposition of biopsy-proven histologic data can allow creation of a mo

147 , or 5 masses assessed at diagnostic US with biopsy-proven histologic findings and BI-RADS 3 masses s

148 A prospective cohort of 84 patients with biopsy-proven HIV+MCD were treated with risk-stratified

149 The study included 214 biopsy-proven HNSCC patients who underwent a posttherapy

150 erials and Methods Consecutive patients with biopsy-proven HRLs who underwent surgery or at least 2 y

151 We recruited patients (18-75 years) with biopsy-proven idiopathic membranous nephropathy, a plasm

152 e of remission duration in 376 patients with biopsy-proven idiopathic/primary MGN who achieved a remi

153 low-up, we randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, ma

154 ohort study included 639 white patients with biopsy-proven IgAN since 1979 (mean age at diagnosis, 40

155 Only cases with biopsy-proven IgG4-RHP were considered and included in t

156 PLA2R1 in a cohort of 95 white patients with biopsy-proven iMN and assessed all 30 exons of PLA2R1, i

157 sarcoidosis was identified in 10.7%, and was biopsy proven in 43.4%.

158 on viral infection of renal allografts, with biopsy-proven incidence of approximately 5%.

159 Forty-four patients with biopsy-proven INCPH were included.

160 All 7 patients had locally advanced, biopsy-proven, infiltrative BCC that was not amenable to

161 tions in an independent set of patients with biopsy-proven inflammation/BPH (n = 61) and prostate can

162 68)Ga-PSMA11) PET/MRI for initial staging of biopsy-proven intermediate- or high-risk PC, and 57 pati

163 uctal carcinoma in situ (DCIS) components of biopsy-proven invasive breast cancer before surgery and

164 enter study of 593 consecutive patients with biopsy-proven invasive breast cancer who underwent breas

165 The data set of biopsy-proven invasive breast cancers included 74 (88%)

166 and analyzed this reactivity in relation to biopsy-proven IRI.

167 cohort of 1426 patients diagnosed as having biopsy-proven KC from January 1, 1999, through December

168 in the folic acid model and in patients with biopsy-proven kidney fibrosis.

169 e masked review of images from patients with biopsy-proven lacrimal gland pathology.

170 al and patient outcomes in 178 patients with biopsy-proven LCCN from 10 centers in Europe and North A

171 ed a nationwide cohort of 255 patients, with biopsy-proven LCDD (n = 212) (including pure LCDD [n = 1

172 Fifty-three patients with biopsy-proven LCDD were prospectively followed at the UK

173 We report 23 patients with biopsy-proven LCH associated with Erdheim-Chester diseas

174 ountries evaluated an RCM study set from 100 biopsy-proven lesions, including 55 melanocytic nevi, 20

175 ive study included consecutive patients with biopsy-proven LM and LMM located on the head and neck ar

176 We identified 606 patients with biopsy proven localised amyloidosis (likely light-chain

177 Cohort A patients had biopsy-proven localized prostate cancer preceding radica

178 red ten men and 25 external controls who had biopsy-proven low-risk prostate cancer and had chosen to

179 (aged >=18 years) with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer (

180 This was a retrospective study of 261 biopsy-proven lung cancer patients at a single tertiary

181 A total of 1,171 patients with biopsy-proven lung cancer who had undergone (18)F-FDG PE

182 A total of 201 patients with biopsy-proven lung cancer, who underwent therapy assessm

183 Newly diagnosed, biopsy-proven malignancies were detected in 8.1% (56 of

184 presentation and outcome of 80 patients with biopsy-proven MCGN, which were identified in the retrosp

185 etrospective study included 51 patients with biopsy-proven MCNS recruited between November 2012 and O

186 posterior left thigh lesion confirmed to be biopsy-proven melanoma.

187 with findings consistent with metastasis had biopsy-proven metastasis.

188 Ten patients with biopsy-proven metastatic cancer were included.

189 oven HER2-negative primary breast cancer and biopsy-proven metastatic disease were enrolled in a pros

190 ropriate management of incompletely excised, biopsy-proven, mild and moderate dysplastic nevi (DN).

191 ve study evaluated consecutive patients with biopsy-proven MIUC who underwent serial cross-sectional

192 There were 167 patients with biopsy-proven MMP who were seen at the Wilmer Eye Instit

193 ed clinical trial involving 98 patients with biopsy-proven myeloma cast nephropathy requiring hemodia

194 e (1) characterized the plasma BA profile in biopsy-proven NAFL and NASH and compared to controls and

195 ded liver sections in subjects (N = 69) with biopsy proven NAFLD and no liver disease (control).

196 - 1Beta) in obese subjects (BMI >/= 35) with biopsy proven NAFLD.

197 lyzed serum metabolomes of 535 patients with biopsy-proven NAFLD (353 with simple steatosis and 182 w

198 iopsies and clinical data from patients with biopsy-proven NAFLD (56 in the discovery cohort and 34 i

199 Sixty-five consecutive children with biopsy-proven NAFLD (age, mean +/- SD, 11.7 +/- 2.1 yr;

200 gated in a cohort of Caucasian patients with biopsy-proven NAFLD (n = 538), lean healthy controls (n

201 Gut microbiome profiles of 171 Asians with biopsy-proven NAFLD and 31 non-NAFLD controls are analyz

202 of 87 children (age range, 8-17 years) with biopsy-proven NAFLD and 37 children with obesity without

203 r enzyme levels in 768 adult Caucasians with biopsy-proven NAFLD and with cirrhosis in the general po

204 ta from 1557 multiethnic adult patients with biopsy-proven NAFLD enrolled into 4 different studies co

205 was conducted in 83 unselected patients with biopsy-proven NAFLD from a single center.

206 e sequencing was performed in a cohort of 83 biopsy-proven NAFLD patients and 13 patients with non-in

207 ta from 229 well-characterized patients with biopsy-proven NAFLD were collected.

208 Children with biopsy-proven NAFLD were eligible for inclusion.

209 Fifty-seven patients with biopsy-proven NAFLD were enrolled.

210 ng 117 consecutive patients (56% women) with biopsy-proven NAFLD who underwent a standardized researc

211 udy included 102 patients (62.7% women) with biopsy-proven NAFLD who underwent contemporaneous MRE an

212 tudied Escherichia coli LPS in patients with biopsy-proven NAFLD, 25 simple steatosis (nonalcoholic f

213 Among children with biopsy-proven NAFLD, 26 had definite nonalcoholic steato

214 in lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatoce

215 142 Caucasian children and adolescents with biopsy-proven NAFLD, presenting to the Liver Unit of the

216 a well-characterized cohort of patients with biopsy-proven NAFLD, this study demonstrates that hepati

217 cterized prospective cohort of patients with biopsy-proven NAFLD, we aimed to examine the longitudina

218 sease activity and severity in patients with biopsy-proven NAFLD.

219 fibrosis in well-characterized patients with biopsy-proven NAFLD.

220 3 or 4) in well-characterized patients with biopsy-proven NAFLD.

221 istology and glucose and lipid metabolism in biopsy-proven NAFLD.

222 study we examined 65 patients with advanced biopsy-proven NASH (fibrosis stage 3-4) and 54 with mild

223 after USPIO administration in patients with biopsy-proven NASH (n = 13), hepatic steatosis without N

224 Two hundred and thirty-six patients with biopsy-proven NASH and bridging fibrosis or cirrhosis se

225 Our aims were to determine whether biopsy-proven NASH impacts clinical outcomes in CHB pati

226 undred and nine morbidly obese patients with biopsy-proven NASH underwent bariatric surgery at the Un

227 , placebo-controlled trial, 50 patients with biopsy-proven NASH were randomized to either ezetimibe 1

228 ients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general popul

229 Key inclusion criteria were biopsy-proven NASH with Nonalcoholic Fatty Liver Disease

230 36 with simple steatosis [SS], and 122 with biopsy-proven NASH).

231 ed trials (RCTs) including 964 patients with biopsy-proven NASH, comparing vitamin E, thiazolidinedio

232 ve study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical researc

233 ) should be considered only in patients with biopsy-proven NASH.

234 I-PDFF) and liver histology in patients with biopsy-proven NASH.

235 sferase and liver histology in patients with biopsy-proven NASH.

236 examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no).

237 were evaluated in the dermatology clinic for biopsy-proven NMSC of the head and neck during the study

238 Clip placement in the biopsy-proven node at diagnosis and evaluation of resect

239 In biopsy-proven node-positive breast cancer after NAC, a l

240 Downstaging of biopsy-proven node-positive patients with neoadjuvant ch

241 lly, plasma DMGV levels were correlated with biopsy-proven nonalcoholic steatohepatitis (NASH) in a h

242 18 patients with biopsy-proven NSCLC (n = 10) or HNSCC (n = 8) were inclu

243 Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for

244 atment and outcomes of 158 first episodes of biopsy-proven pancreas rejection between 1 January 1997

245 th borderline resectable or locally advanced biopsy-proven pancreatic ductal adenocarcinoma, an Easte

246 In this study, 43 biopsy-proven patient data identified as diffuse infiltr

247 itis (RAVE) Trial who had renal involvement (biopsy proven pauci-immune GN, red blood cell casts in t

248 Ten patients with biopsy-proven PCa (5 with primary PCa and 5 with prostat

249 Materials and Methods Eighteen patients with biopsy-proven PCa provided informed consent to be includ

250 We studied 224 cases of biopsy-proven PLA2R-negative MN and 102 controls (includ

251 Patients with biopsy-proven PMN and nephrotic syndrome after 6 months

252 aim of our study was to evaluate the tissue biopsy-proven positive predictive value (PPV3) for BI-RA

253 Medically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to

254 ded were 63 kidney allograft recipients with biopsy proven primary MN followed up for 77.0 (39-113) m

255 Two patients with biopsy-proven primary refractory HL were treated off-stu

256 , 1 cohort) in patients undergoing elective, biopsy-proven, primary non-metastatic colorectal cancer

257 at enrolled 478 men aged 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Soc

258 Twenty-one patients with biopsy-proven prostate cancer underwent (68)Ga-PSMA-HBED

259 istry was used to identify all patients with biopsy-proven PTLD for the period 2000-2014.

260 ur patients (46% men) with single, sporadic, biopsy-proven RCC (median size +/- standard deviation, 2

261 ), study participants with single, sporadic, biopsy-proven RCC were included to calculate the 10-year

262 In this case series, 3 patients with biopsy-proven recalcitrant HHD were evaluated in the out

263 an lead time between ctHPVDNA positivity and biopsy-proven recurrence was 3.9 months (range, 0.37-12.

264 surveillance, 15 of whom were diagnosed with biopsy-proven recurrence.

265 e ctHPVDNA blood tests, 15 of whom developed biopsy-proven recurrence.

266 ained virological response, and may induce a biopsy-proven regression of liver fibrosis in a liver tr

267 nt of de novo donor specific antibody and/or biopsy proven rejection) and infection events (viremia/v

268 ely postoperatively, and a trend toward more biopsy-proven rejection (P = 0.073).

269 te between 6 months and last follow-up), and biopsy-proven rejection after 6 months.

270 d graft survival, a significant incidence of biopsy-proven rejection occurred in this subset of close

271 Biopsy-proven rejection was defined according to the Ban

272 de viremia was independently associated with biopsy-proven rejection within 12 months (p=0.045) post-

273 s included patient survival, graft survival, biopsy-proven rejection, and infectious or noninfectious

274 postoperative events, such as renal failure, biopsy-proven rejection, and stroke.

275 cardiac allograft recipients at the time of biopsy-proven rejection.

276 nd predicted ACR events up to 40 days before biopsy-proven rejection.

277 TV-DNA levels decreased significantly before biopsy-proven rejection.

278 The spectrum of biopsy proven renal diseases differs between locations a

279 men; mean age, 71.9 years +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with t

280 yzed data from 164 consecutive patients with biopsy-proven renal involvement of ANCA-associated vascu

281 Only patients with uveitis and presumed or biopsy-proven sarcoidosis (N = 113) were included.

282 retrospective cohort study of patients with biopsy-proven sarcoidosis and known or suspected cardiac

283 ients at Duke University Medical Center with biopsy-proven sarcoidosis and SAPH confirmed by right he

284 with dual diagnoses of uveitis and presumed/biopsy-proven sarcoidosis.

285 an ex vivo pilot study involving 10 cases of biopsy-proven sarcoma and we propose a quantitative meth

286 centers and included 123 patients, with 132 biopsy-proven screening-detected cancers, and 52 examina

287 treated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent bot

288 , 18-75 y) with recent onset of jaundice and biopsy-proven severe AH in our study, performed at 18 ho

289 vaccine and then compared with the number of biopsy-proven skin cancers recorded over a similar perio

290 Biopsy-proven skin cancers were recorded for 16 months (

291 d to the British Columbia Cancer Agency with biopsy-proven stage I to III breast cancer (BC), diagnos

292 SA, enrolling patients with newly diagnosed, biopsy-proven stage III or IV squamous-cell carcinoma of

293 raft recipients showed a higher incidence of biopsy-proven (sub)clinical AMR (P = 0.032) and a higher

294 A consecutive series of 55 patients with biopsy-proven SUSCC without bone invasion treated by wid

295 Materials and Methods A total of 1425 biopsy-proven thyroid nodules from 1264 consecutive pati

296 dy included 691 consecutive newly diagnosed, biopsy-proven, treatment-naive, D'Amico high-risk PCa pa

297 Methods In this prospective study, men with biopsy-proven, treatment-naive, low- to intermediate-ris

298 edictive value (95% CI 54-96) for underlying biopsy-proven usual interstitial pneumonia.

299 Tumor recurrence was defined as biopsy-proven vital tumor at the initial tumor site.

300 Eligibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 a